Trade CareDx Inc - CDNA CFD

CareDx, Inc Company profile

About CareDx Inc

CareDx, Inc. is a precision medicine company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company’s commercially available testing services consist of AlloSure Kidney, which is a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients, AlloMap Heart, which is a gene expression solution for heart transplant patients, and AlloSure Heart, a dd-cf-DNA solution for heart transplant patients. Its suite of AlloSeq products include: AlloSeq Tx, AlloSeq cfDNA, AlloSeq HCT, TruSight HLA, Olerup SSP and QTYPE. It also provides transplant patient tracking software, Ottr software, as well as of transplant quality tracking and waitlist management solutions.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, CareDx Inc revenues increased 54% to $296.4M. Net loss increased 64% to $30.7M. Revenues reflect United States segment increase of 55% to $282M, Europe segment increase of 30% to $9.8M. Higher net loss reflects R & D increase of 57% to $69.4M (expense), Sales and marketing increase of 58% to $60.6M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.40 to -$0.59.

Equity composition

Common Stock $0.001 Par, 100M auth., 11,570,552 issd,. Insiders owns approx. 34.57%.